Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585826 | 1.00 | GPR119 (0.50) | GPR119NR1H2FAAHHPGDKDM4E | |
| SCHEMBL25223837 | 0.99 | GPR119 (0.51) | GPR119NR1H2FAAHHPGDKDM4E | |
| SCHEMBL7920172 | 0.96 | GPR119 (0.49) | GPR119NR1H2FAAHHPGDKDM4E | |
| SCHEMBL23006759 | 0.96 | GPR119 (0.49) | GPR119NR1H2FAAHHPGDKDM4E | |
| SCHEMBL2187082 | 0.96 | GPR119 (0.49) | GPR119NR1H2FAAHHPGDKDM4E | |
| SCHEMBL1576008 | 0.93 | GPR119 (0.56) | GPR119NR1H2FAAHHPGDKDM4E | |
| SCHEMBL30663073 | 0.92 | MEN1 (0.50) | GPR119NR1H2HPGDMEN1ALDH1A1 | |
| SCHEMBL30662966 | 0.92 | MEN1 (0.50) | GPR119NR1H2HPGDMEN1ALDH1A1 | |
| SCHEMBL5231864 | 0.92 | MEN1 (0.50) | GPR119NR1H2HPGDMEN1ALDH1A1 | |
| SCHEMBL23499817 | 0.91 | GPR119 (0.57) | GPR119FAAHHPGDKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863804-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2007-12-12 | — | — | EP | disclosed |
| US-20060264415-A1 | Inhibitors of histone deacetylase | METHYLGENE INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006102760-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264415-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC3, HDAC11 | GPR119 1328/4885NR1H2 544/4885FAAH 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.